SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD OCT 05
MCX SILVER SEP 04
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD OCT 05
MCX SILVER SEP 04
MCX CRUDEOIL AUG 19
MCX NATURALGAS AUG 26
USD/INR
EUR/INR
GBP/INR
JPY/INR

This mid-cap pharma stock turned Rs 1,00,000 to Rs 3,17,000 in just four months

Global stocks on defensive as US-China tensions spook investors

Oil prices slip on uncertainty over US recovery, stimulus

Rupee ends marginally lower; appreciates by 0.24% for the week

Healthcare

Pune's Serum Institute aims to launch Oxford's COVID-19 vaccine by October if trials succeed

Updated : April 24, 2020 08:18 PM IST

Pune-based Serum Institute of India on Friday said it expects vaccine for COVID-19 developed by the University of Oxford in the market by October if safety and efficacy is established.

The institute has partnered with the Oxford vaccine project as one of the seven global institutions behind manufacturing the vaccine.

In an interview to CNBC-TV18, Adar Poonawalla, chief executive officer, said, "If the vaccine works in the UK trial and we do another trial in India which we are hoping to start shortly, in safety and efficacy, only then will it be available by October or November and that is only if we start producing at our personal cost in risk by the end of this month."

Further, he said the institute will be using one of the existing facilities for manufacturing COVID-19 vaccine, "However, it will take over two years to set up new manufacturing facility for COVID-19 vaccine."

"Typically vaccines take many years but with the regulatory approvals in India that have been very carefully changed for this product development, we are very pleased to announce that we will be able to do it by the end of this year," Poonawalla said.

According to the current target, the institute is looking for 4-5 million doses monthly and will start manufacturing early in hopes that vaccine trial will be successful to save time, he added, "So, we hope to build up 20-40 million doses by September-October in the hope that if the trial works, then we will have this product."

"We are not a listed company and we are not accountable for our actions to investors in terms of pure profits and returns. So, I was able to make this decision and take this risk on at the cost of our other vaccines that we are putting aside temporarily so that we can build up the scale here," he said.

"The manufacturing plant in Pune will have an investment of Rs 500-600 crore that we have already done for one of the vaccines and until we build a brand new facility for COVID-19 which will take two years. So, I have decided to dedicate one of my existing facilities for this in the interest of public health and so that we can rapidly scale up the production in this manner," he added.

Poonawalla said the institute will be partnering with the Indian Council for Medical Research (ICMR) to do clinical trials and is in touch with Department of Biotechnology (DBT).

You May Also Like

Air India Express IX 1344 flight touched down 1,000 metres from beginning of runway

Air India Express IX 1344 flight touched down 1,000 metres from beginning of runway

This mid-cap pharma stock turned Rs 1,00,000 to Rs 3,17,000 in just four months

This mid-cap pharma stock turned Rs 1,00,000 to Rs 3,17,000 in just four months

This Tata Group company stock has risen almost 150% in 4 months

This Tata Group company stock has risen almost 150% in 4 months

Trending on CNBC-TV18

Live TV

recommended for you